Search bioRxiv⌕ Search

Biology subjects

Huebner, H.

Publications and source records attributed to Huebner, H..

2 recordsLinked to original sources

Inhibiting a promiscuous GPCR: iterative discovery of bitter taste receptor ligands

The human GPCR family comprises circa 800 members, activated by hundreds of thousands of compounds. Bitter taste receptors, TAS2Rs, constitute a large and distinct subfamily, expressed orally and extra-orally and involved in physiological and pathological conditions. TAS2R14 is the most promiscuous member, with over 150 agonists and 3 antagonists known prior to this study. Due to the scarcity of inhibitors and to the importance of chemical probes for exploring TAS2R14 functions, we aimed to discover new ligands for this receptor, with emphasis on antagonists. To cope with the lack of experimental structure of the receptor, we used a mixed experimental/computational methodology which iteratively improved the performance of the predicted structure. The increasing number of active compounds, obtained here through experimental screening of FDA-approved drug library, and of chemically synthesized flufenamic acid derivatives, enabled the refinement of the binding pocket, which in turn improved the structure-based virtual screening reliability. This mixed approach led to the identification of 10 new antagonists and 200 new agonists of TAS2R14, illustrating the untapped potential of rigorous medicinal chemistry for TAS2Rs. The iterative framework suggested residues involved in the activation process, is suitable for expanding bitter and bitter-masking chemical space, and is applicable to other promiscuous GPCRs lacking experimental structures. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=172 SRC="FIGDIR/small/517821v4_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@30bd42org.highwire.dtl.DTLVardef@1d94fbforg.highwire.dtl.DTLVardef@2858borg.highwire.dtl.DTLVardef@18d9af2_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioinformatics↗

Structure-based Evolution of G protein-biased μ-opioid Receptor Agonists

The -opioid receptor (OR) is the major target for opioid analgesics. Activation of OR initiates signaling through G protein pathways as well as through {beta}-arrestin recruitment. OR agonists that are biased towards G protein signaling pathways demonstrate diminished side effects. PZM21, discovered by computational docking, is a G protein biased OR agonist. Here we report the cryoEM structure of PZM21 bound OR in complex with Gi protein. Structure-based evolution led to multiple PZM21 analogs with more pronounced Gi protein bias and increased lipophilicity to improve CNS penetration. Among them, FH210 shows extremely low potency and efficacy for arrestin recruitment. We further determined the cryoEM structure of FH210 bound to OR in complex with Gi protein and confirmed its expected binding pose. The structural and pharmacological studies reveal a potential mechanism to reduce {beta}-arrestin recruitment by the OR, and hold promise for developing next-generation analgesics with fewer adverse effects. Table of Contents Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=43 SRC="FIGDIR/small/485330v1_ufig1.gif" ALT="Figure 1"> View larger version (14K): org.highwire.dtl.DTLVardef@125808corg.highwire.dtl.DTLVardef@11aa15corg.highwire.dtl.DTLVardef@157caaaorg.highwire.dtl.DTLVardef@ba837d_HPS_FORMAT_FIGEXP M_FIG C_FIG We obtained cryoEM structures of the -opioid receptor (OR) bound to the lead compound PZM21 and the newly developed agonist FH210 to understand the mechanism of their biased signaling and to guide the evolution of next-generation analgesics with fewer adverse effects.

pharmacology and toxicology↗